Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alteon (ALT) -- Ignore unavailable to you. Want to Upgrade?

To: Mac S. Giballa who wrote (186)	12/8/1997 4:33:00 PM
From: Bill Tomko	Respond to of 318

my point exactly. The only thing I would add to your comment is amen!

To: Mac S. Giballa who wrote (186)	12/8/1997 4:34:00 PM
From: Rudy Saucillo	Respond to of 318

Actually, Scott, if you go back and read #132, I estimated a minimum of $10/share if we had strong ESRD results and a major partnership. We're at 9-3/16 as I type and moving ahead. But at least we agree there's much more to go over the next several years as the Phase III studies come in, ALTN files and eventually gets approval for Pimagedine. Now that ALTN has cash to properly fund its preclinical work, I would expect to see good progress here, also. BTW, estimates are a dime a dozen and don't mean much w/o some minimal analysis, principal assumptions, etc. As a ROM estimate, AMLN is probably a good "case study" for ALTN holders assuming a strong market next year. They reached a market cap of $500 million prior to releasing data from their first several Phase III studies. Given a cooperating market, I would expect ALTN to be at least that strong. Rudy